Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability. We conducted an open-label, randomized, noninferiority, phase III trial comparing acalabrutinib and ibrutinib in patients with ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Byrd, John C., Hillmen, Peter, Ghia, Paolo, Kater, Arnon P., Chanan-Khan, Asher, Furman, Richard R., O'Brien, Susan, Yenerel, Mustafa Nuri, Illés, Arpad, Kay, Neil, Garcia-Marco, Jose A., Mato, Anthony, Pinilla-Ibarz, Javier, Seymour, John F., Lepretre, Stephane, Stilgenbauer, Stephan, Robak, Tadeusz, Rothbaum, Wayne, Izumi, Raquel, Hamdy, Ahmed, Patel, Priti, Higgins, Kara, Sohoni, Sophia, Jurczak, Wojciech
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547923/
https://www.ncbi.nlm.nih.gov/pubmed/34310172
http://dx.doi.org/10.1200/JCO.21.01210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547923/
https://www.ncbi.nlm.nih.gov/pubmed/34310172
http://dx.doi.org/10.1200/JCO.21.01210

Ejemplares similares